Approval after phase I: ceritinib runs the three-minute mile.
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA bchabner@partners.org.
Bruce A
BA
Chabner
D017321:Clinical Trials, Phase I as Topic; D017277:Drug Approval; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D013450:Sulfones / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D011743:Pyrimidines; D013450:Sulfones; C586847:ceritinib